ArticleBMC infectious diseases2026
Clinical characteristics of childhood tuberculous meningitis and risk factors for severe neurological sequelae disaggregated by age group.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Incidental Papilledema Revealing Neurotuberculosis: A Case Report of a Diagnostic Challenge.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveChildhood tuberculous meningitis (TBM) often leads to death or severe neurological sequelae. We aimed to evaluate clinical characteristics of childhood TBM and identify risk factors for severe neurological sequelae.
methodsA retrospective analysis was conducted on the consecutive clinical data of inpatient with TBM under 15 years admitted to Shanghai Public Health Clinical Center from 2013 to 2024. Patients were divided into two age groups: <5 yearsand 5–14 years. Demographic characteristics, clinical symptoms, laboratory tests, imaging findings, treatment regimens, and outcomes at 12 months post-treatment were compared between the two groups. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors for severe neurological sequelae.
resultsThis study enrolled 107 children, 61 under 5 years (57.0%), and 46 were 5–14 years (43.0%). The < 5 years group had a higher proportion of TBM stage III cases (29.5% vs. 2.2%, p <0.001) than the 5–14 years group. The < 5 years group had higher proportions of concurrent pulmonary tuberculosis, altered consciousness, signs of increased intracranial pressure, hydrocephalus, and ventricular enlargement compared to the 5–14 years group. At the same time, the Glasgow Coma Scale score was significantly lower. At 12 months post-treatment, the < 5 years group showed significantly higher rates of unfavourable prognosis and drug-induced liver injury. The incidence of severe neurological sequelae was 20.6% (22/107). Univariate regression revealed that TBM stage III, altered consciousness, coma, signs of upper motor neuron damage, hydrocephalus, and external ventricular drainage were associated with severe neurological sequelae. Multivariate regression identified coma as an independent risk factor for severe neurological sequelae in pediatric TBM (aOR = 6.17, 95% CI: 1.94–19.56, P = 0.002).
conclusionThis study demonstrates that younger children (< 5 years) with TBM present with more severe conditions, higher complication rates, and poorer prognoses. Coma is an independent risk factor for severe neurological sequelae. In clinical practice, early recognition of TBM in younger children and aggressive comprehensive treatment for comatose patients should be emphasized to facilitate the development of early individualized intervention strategies and optimize treatment outcomes for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.